COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF SUNITINIB VS SORAFENIB AND BEVACIZUMAB plus INTERFERON-ALFA AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN MEXICO

被引：1
|
作者：
Salinas-Escudero, G. [1 ]
Contreras-Hernandez, I [2 ]
Mould-Quevedo, J. [3 ]
机构：
[1] Hosp Infantil Mexico Fed Gomez, Mexico City, DF, Mexico
[2] Social Secur Mexican Inst, Mexico City, DF, Mexico
[3] Pfizer Mexico, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)75353-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma
    Liu, Ruizhe
    Qiu, Kaifeng
    Wu, Junyan
    Jiang, Yanqing
    Wu, Peihao
    Pang, Jianxin
    IMMUNOTHERAPY, 2022, 14 (11) : 859 - 869
  • [42] Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
    Chen, Jun
    Hu, Gaoyun
    Chen, Zhuo
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    Cheng, Zeneng
    CLINICAL DRUG INVESTIGATION, 2019, 39 (10) : 931 - 938
  • [43] A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
    Lu, Peiyao
    Liang, Weiting
    Li, Jiahao
    Hong, Yanming
    Chen, Zhuojia
    Liu, Tao
    Dong, Pei
    Huang, Hongbing
    Zhang, Tiantian
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [44] An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy
    Capri, Stefano
    Porta, Camillo
    Condorelli, Claudia
    Premoli, Eleonora
    Khare, Ankur
    Kalra, Manik
    Modi, Niraj
    Ratto, Barbara
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1579 - 1587
  • [45] Cost-effectiveness of sunitinib in metastatic renal cell carcinoma
    Purmonen, Timo T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (04) : 383 - 393
  • [46] Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC)
    Remak, E.
    Mullins, C. D.
    Akobundu, E.
    Charbonneau, C.
    Woodruff, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Cost of adverse events of bevacizumab plus interferon-alpha2a, compared to sunitinib in the first-line treatment of metastatic renal cell cancer
    Carlos-Rivera, Fernando
    Ramirez-Gamez, Jocelyn
    Aguirre-Granados, Araceli
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (06): : 255 - 265
  • [48] Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [49] Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    He, Xiaofeng
    Tang, Ruilei
    Du, Zedong
    Zhou, Jing
    Zhang, Jian
    Li, Qiu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (07) : 853 - 859
  • [50] COST EFFECTIVENESS OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN CHINA
    Shi, Q.
    Yin, H.
    Xuan, J.
    Wu, Y.
    Cheng, G.
    VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
12345